IFP Advisors’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $559K | Sell |
6,175
-806
| -12% | -$67.5K | 0.01% | 990 |
|
|
2026
Q1 | $559K | Sell |
6,981
-5,527
| -44% | -$456K | 0.01% | 916 |
|
|
2025
Q4 | $1.07M | Buy |
12,508
+5,807
| +87% | +$477K | 0.02% | 636 |
|
|
2025
Q3 | $521K | Buy |
6,701
+156
| +2% | +$12.2K | 0.01% | 848 |
|
|
2025
Q2 | $512K | Buy |
6,545
+442
| +7% | +$33K | 0.01% | 829 |
|
|
2025
Q1 | $442K | Buy |
6,103
+3,246
| +114% | +$232K | 0.01% | 816 |
|
|
2024
Q4 | $211K | Sell |
2,857
-646
| -18% | -$45.2K | 0.01% | 1107 |
|
|
2024
Q3 | $231K | Sell |
3,503
-1,384
| -28% | -$101K | 0.01% | 1021 |
|
|
2024
Q2 | $451K | Buy |
4,887
+919
| +23% | +$81.4K | 0.02% | 692 |
|
|
2024
Q1 | $379K | Sell |
3,968
-1,053
| -21% | -$88.5K | 0.02% | 702 |
|
|
2023
Q4 | $383K | Buy |
5,021
+553
| +12% | +$38.5K | 0.02% | 675 |
|
|
2023
Q3 | $310K | Sell |
4,468
-472
| -10% | -$37.9K | 0.01% | 765 |
|
|
2023
Q2 | $466K | Buy |
4,940
+858
| +21% | +$74.6K | 0.02% | 682 |
|
|
2023
Q1 | $579K | Sell |
4,082
-7,754
| -66% | -$609K | 0.03% | 549 |
|
|
2022
Q4 | $1.69M | Sell |
11,836
-719
| -6% | -$55.4K | 0.05% | 424 |
|
|
2022
Q3 | $1.79M | Buy |
12,555
+930
| +8% | +$89.5K | 0.05% | 439 |
|
|
2022
Q2 | $1.65M | Hold |
11,625
| – | – | 0.05% | 406 |
|
|
2022
Q1 | $1.65M | Buy |
11,625
+8,033
| +224% | +$901K | 0.05% | 406 |
|
|
2021
Q4 | $466K | Sell |
3,592
-62
| -2% | -$7.23K | 0.01% | 618 |
|
|
2021
Q3 | $415K | Sell |
3,654
-23
| -0.6% | -$2.63K | 0.01% | 647 |
|
|
2021
Q2 | $379K | Sell |
3,677
-14,341
| -80% | -$1.35M | 0.01% | 637 |
|
|
2021
Q1 | $1.51M | Buy |
18,018
+6,234
| +53% | +$527K | 0.03% | 291 |
|
|
2020
Q4 | $1.07M | Buy |
11,784
+1,523
| +15% | +$126K | 0.04% | 331 |
|
|
2020
Q3 | $820K | Buy |
10,261
+637
| +7% | +$49.7K | 0.05% | 327 |
|
|
2020
Q2 | $648K | Sell |
9,624
-1,473
| -13% | -$105K | 0.05% | 357 |
|
|
2020
Q1 | $741K | Buy |
11,097
+252
| +2% | +$18.2K | 0.07% | 267 |
|
|
2019
Q4 | $847K | Sell |
10,845
-1,419
| -12% | -$111K | 0.06% | 318 |
|
|
2019
Q3 | $889K | Buy |
+12,264
| New | +$861K | 0.06% | 332 |
|
|
2019
Q1 | $108K | Sell |
1,686
-11,295
| -87% | -$645K | 0.01% | 661 |
|
|
2018
Q4 | $651K | Buy |
12,981
+63
| +0.5% | +$3.19K | 0.04% | 462 |
|
|
2018
Q3 | $750K | Buy |
12,918
+438
| +4% | +$21.4K | 0.03% | 526 |
|
|
2018
Q2 | $606K | Sell |
12,480
-1,800
| -13% | -$84K | 0.03% | 588 |
|
|
2018
Q1 | $536K | Hold |
14,280
| – | – | 0.02% | 598 |
|
|
2017
Q4 | $536K | Sell |
14,280
-7,392
| -34% | -$271K | 0.02% | 599 |
|
|
2017
Q3 | $790K | Buy |
21,672
+1,464
| +7% | +$55.8K | 0.03% | 516 |
|
|
2017
Q2 | $796K | Buy |
20,208
+1,341
| +7% | +$48.9K | 0.03% | 499 |
|
|
2017
Q1 | $592K | Sell |
18,867
-120
| -0.6% | -$3.76K | 0.03% | 597 |
|
|
2016
Q4 | $593K | Sell |
18,987
-1,842
| -9% | -$59.7K | 0.03% | 551 |
|
|
2016
Q3 | $837K | Buy |
20,829
+4,476
| +27% | +$169K | 0.04% | 405 |
|
|
2016
Q2 | $544K | Buy |
16,353
+14,667
| +870% | +$502K | 0.03% | 519 |
|
|
2016
Q1 | $108K | Sell |
1,686
-26,220
| -94% | -$723K | 0.01% | 661 |
|
|
2015
Q4 | $735K | Buy |
+27,906
| New | +$725K | 0.05% | 380 |
|
Other funds holding EW
IFP Advisors's EW Position: Q2 2026 in Review
IFP Advisors reduced its Edwards Lifesciences (EW) stake by 12% in Q2 2026, selling an estimated $67.5K and leaving 6,175 shares worth $559K. The position accounts for 0.01% of the portfolio, ranked #990.
IFP Advisors first reported a position in EW in Q4 2015 and has held it in 42 quarters since. The position peaked at $1.79M in Q3 2022. 1,327 funds tracked by Wall St. Rank hold EW as of Q2 2026.
- IFP Advisors held 6,175 shares of Edwards Lifesciences worth $559K as of Q2 2026.
- IFP Advisors sold 806 Edwards Lifesciences shares in Q2 2026, an estimated $67.5K.
- Edwards Lifesciences made up 0.01% of IFP Advisors's portfolio in Q2 2026, its #990 holding.
- IFP Advisors first reported a position in Edwards Lifesciences in Q4 2015 and has held it in 42 quarters since.
- IFP Advisors's Edwards Lifesciences position peaked at $1.79M in Q3 2022.
- 1,327 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.
Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.